Glucagon-like peptide-1 and insulin synergistically activate vagal afferent neurons. (October 2017)
- Record Type:
- Journal Article
- Title:
- Glucagon-like peptide-1 and insulin synergistically activate vagal afferent neurons. (October 2017)
- Main Title:
- Glucagon-like peptide-1 and insulin synergistically activate vagal afferent neurons
- Authors:
- Iwasaki, Yusaku
Goswami, Chayon
Yada, Toshihiko - Abstract:
- Abstract: Intestinal glucagon-like peptide-1 (GLP-1) and pancreatic insulin, released postprandially, commonly regulate glucose metabolism. Recent clinical experience indicates that the GLP-1R agonist and insulin in combination, compared to insulin alone, results in better glycemic and weight controls in type 2 diabetic patients. These observations suggest possible interactive effect of these hormones. These hormones, in addition to peripherally controlling glycemia, exert central regulation of food intake and glucose metabolism, the effect at least partly mediated by signaling to the brain via the vagal afferents. However, whether the vagal afferents are involved in the interactive effects of GLP-1 and insulin remains unknown. The present study explored possible cooperative effect of GLP-1 and insulin on vagal afferent neurons isolated from nodose ganglion (NG) of mice, while monitoring the neuronal activity by measuring cytosolic Ca 2+ concentration ([Ca 2+ ]i ) with fura-2. GLP-1 at 10 −8 M increased [Ca 2+ ]i in 8–11% of single NG neurons. GLP-1-induced [Ca 2+ ]i increases were inhibited by GLP-1 receptor antagonist exendin (9–39). Majority (92%) of GLP-1-responseive NG neurons also responded to 10 −7 M insulin with [Ca 2+ ]i increases. Both GLP-1 and insulin at lower concentration of 10 −9 M induced [Ca 2+ ]i increases with smaller amplitude in lesser NG neuron population (4–7%). These hormones at 10 −9 M in combination recruited the unresponsive neurons to [Ca 2+Abstract: Intestinal glucagon-like peptide-1 (GLP-1) and pancreatic insulin, released postprandially, commonly regulate glucose metabolism. Recent clinical experience indicates that the GLP-1R agonist and insulin in combination, compared to insulin alone, results in better glycemic and weight controls in type 2 diabetic patients. These observations suggest possible interactive effect of these hormones. These hormones, in addition to peripherally controlling glycemia, exert central regulation of food intake and glucose metabolism, the effect at least partly mediated by signaling to the brain via the vagal afferents. However, whether the vagal afferents are involved in the interactive effects of GLP-1 and insulin remains unknown. The present study explored possible cooperative effect of GLP-1 and insulin on vagal afferent neurons isolated from nodose ganglion (NG) of mice, while monitoring the neuronal activity by measuring cytosolic Ca 2+ concentration ([Ca 2+ ]i ) with fura-2. GLP-1 at 10 −8 M increased [Ca 2+ ]i in 8–11% of single NG neurons. GLP-1-induced [Ca 2+ ]i increases were inhibited by GLP-1 receptor antagonist exendin (9–39). Majority (92%) of GLP-1-responseive NG neurons also responded to 10 −7 M insulin with [Ca 2+ ]i increases. Both GLP-1 and insulin at lower concentration of 10 −9 M induced [Ca 2+ ]i increases with smaller amplitude in lesser NG neuron population (4–7%). These hormones at 10 −9 M in combination recruited the unresponsive neurons to [Ca 2+ ]i increases, and induced [Ca 2+ ]i increases with greater amplitude in the responsive neurons. The results demonstrate that GLP-1 and insulin synergistically and additively activate vagal afferent neurons. This interaction may be linked to the postprandial functions mediated commonly by GLP-1 and insulin and in the beneficial outcome of the therapy with GLP-1 receptor agonist and insulin in combination. Highlights: 10 − 10 –10 −7 M GLP-1 via GLP-1 receptor raise [Ca 2+ ]i in vagal afferent neuron (VAN). GLP-1 and insulin target the common VAN subpopulation to raise [Ca 2+ ]i . GLP-1 and insulin at low dose synergistically and additively raise [Ca 2+ ]i in VAN. GLP-1 and insulin cooperatively activate VAN possibly for glycemic/feeding control. This may underlie beneficial effects of combined GLP-1 agonist + insulin treatment. … (more)
- Is Part Of:
- Neuropeptides. Volume 65(2017)
- Journal:
- Neuropeptides
- Issue:
- Volume 65(2017)
- Issue Display:
- Volume 65, Issue 2017 (2017)
- Year:
- 2017
- Volume:
- 65
- Issue:
- 2017
- Issue Sort Value:
- 2017-0065-2017-0000
- Page Start:
- 77
- Page End:
- 82
- Publication Date:
- 2017-10
- Subjects:
- GLP-1 -- Insulin -- Nodose ganglion -- Combination -- Synergy -- Diabetes
Neuropeptides -- Periodicals
Neuropeptides
Neuropeptides -- Périodiques
Neuropeptides
Electronic journals
Periodicals
572.65 - Journal URLs:
- http://firstsearch.oclc.org ↗
http://firstsearch.oclc.org/journal=0143-4179;screen=info;ECOIP ↗
http://www.harcourt-international.com/journals ↗
http://www.idealibrary.com/cgi-bin/links/toc/npep ↗
http://www.sciencedirect.com/science/journal/01434179 ↗
http://www.clinicalkey.com/dura/browse/journalIssue/01434179 ↗
http://www.clinicalkey.com.au/dura/browse/journalIssue/01434179 ↗
http://www.elsevier.com/journals ↗ - DOI:
- 10.1016/j.npep.2017.05.003 ↗
- Languages:
- English
- ISSNs:
- 0143-4179
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 6081.516000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 5026.xml